Sanofi Ventures is a venture capital that invests in early-stage biotech as well as digital health companies that have innovative ideas and transformative projects.
Leading companies that are finding solutions for rare diseases, oncology, immunology, inflammation, vaccines, as well as digital health solutions are the primary target for Sanofi Ventures. Sanofi Ventures is interested in companies such as Aetion, Click Therapeutics, Common Sensing, Curisium, evidation, Expansion Therapeutics, Fulcrum Therapeutics, and icosavax.
Timeline
Funded Companies
A biotechnology company specializing in creating therapeutics for neurological disorders. It was founded in 2014 and is located in New York City.
A biotechnology company in Washington that focuses on developing safe and effective vaccines against infectious diseases.
Evidation Health is a health and measurement company providing technical support to biopharmaceutical and healthcare companies.
Kymera Therapeutics is a Cambridge, Massachusetts-based biotechnology company specialized in the field of targeted protein degradation.
Yumanity Therapeutics is a Cambridge, Massachusetts-based biotechnology company that transforms drug discovery for diseases caused by protein misfolding.
Veralox Therapeutics is a small molecule drug discovery and development firm based in the Frederick Innovative Technology Center, Inc.
Escient Pharmaceuticals is a San Diego-based company.
People
Further reading
Documentaries, videos and podcasts
Companies
References
Company attributes
Categories
Related Topics
Contributors
- 1
Daniel Frumkin
Mechanical engineering, cryptocurrencies, AI, and travel. - 2
Reys Phillips
A graduate of Cleveland State University with a Bachelor of Science in Education. My main hobbies include story writing and reading. - 3
Edita Rexha
Economist - 4
Aime Anne Nisay
QA Engineer of web and mobile applications - 5
Neelam Jhaveri
Techno Geek + Gamer + Fashionista + Sense of Humor = It's ME - 6
Stefan Steinbauer
A civil engineer who stumbled into coding and fell in love with marketing. Do I need to say more?